Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome.

Trial Profile

Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2013

At a glance

  • Drugs Cetrorelix; Ganirelix
  • Indications Ovarian hyperstimulation syndrome
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 30 Mar 2012 Planned end date changed from 1 Jun 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 28 Jun 2011 New source identified and integrated (European Clinical Tials Database)
    • 06 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top